Pfizer and BioNTech announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19.
Dive into the digital evolution of clinical trials
from Outsourcing-Pharma.com
COVID-19 collaboration to study patient risk via blood
from Outsourcing-Pharma.com
Janssen partners with Koa Health on digital depression treatments
from Outsourcing-Pharma.com
NIAID kicks off fourth iteration of COVID-19 trial
from Outsourcing-Pharma.com
Are stable producer cells the future of viral vector manufacturing and when will allogeneic cell therapy take hold?
COVID-19
BioNTech & InstaDeep launch AI innovation lab for next-generation vaccines and biopharmaceuticals
COVID-19
BioInvent inks antibody manufacturing agreement with Cantargia
Pipelines
Compulsory licensing is not an effective policy tool, warns EU biopharma group as it reacts to European IP action plan
COVID-19
